Sabra Healthcare REIT (SBRA) Earns Daily Media Impact Rating of 0.27
News coverage about Sabra Healthcare REIT (NASDAQ:SBRA) has trended positive recently, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sabra Healthcare REIT earned a coverage optimism score of 0.27 on Accern’s scale. Accern also gave press coverage about the real estate investment trust an impact score of 46.1728807931018 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Brokerages Expect Sabra Healthcare REIT, Inc. (SBRA) Will Announce Quarterly Sales of $118.63 Million (americanbankingnews.com)
- SunTrust Banks Equities Analysts Increase Earnings Estimates for Sabra Healthcare REIT, Inc. (SBRA) (americanbankingnews.com)
- Sabra Healthcare REIT, Inc. (SBRA) Rating Reiterated by SunTrust Banks, Inc. (americanbankingnews.com)
- Brokerages Expect Sabra Healthcare REIT, Inc. (SBRA) to Announce $0.66 Earnings Per Share (americanbankingnews.com)
- Sabra Healthcare REIT, Inc. (SBRA) Stock Rating Reaffirmed by Mizuho (americanbankingnews.com)
A number of equities research analysts recently commented on SBRA shares. BidaskClub raised shares of Sabra Healthcare REIT from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Jefferies Group LLC raised shares of Sabra Healthcare REIT from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Tuesday, August 15th. Zacks Investment Research raised shares of Sabra Healthcare REIT from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Tuesday, August 29th. Cantor Fitzgerald reissued a “buy” rating and set a $30.00 target price on shares of Sabra Healthcare REIT in a report on Friday, September 8th. Finally, ValuEngine raised shares of Sabra Healthcare REIT from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. Sabra Healthcare REIT currently has a consensus rating of “Hold” and an average target price of $25.30.
Shares of Sabra Healthcare REIT (NASDAQ SBRA) opened at 21.54 on Wednesday. Sabra Healthcare REIT has a one year low of $19.30 and a one year high of $29.10. The firm’s 50-day moving average is $22.16 and its 200-day moving average is $24.03. The company has a market cap of $1.41 billion, a PE ratio of 18.13 and a beta of 0.88.
About Sabra Healthcare REIT
Sabra Health Care REIT, Inc is a real estate investment trust. The Company, through its subsidiaries, owns and invests in real estate serving the healthcare industry. The Company’s segment includes investments in healthcare-related real estate properties. The Company’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector.
Receive News & Stock Ratings for Sabra Healthcare REIT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sabra Healthcare REIT Inc. and related stocks with our FREE daily email newsletter.